Injectable lipolysis deoxycholate or mesotherapy evidence for Submental fat

Abstract summary (English) PURPOSE: Submental fat (SMF) accumulation can affect self-image and psychological well-being, leading to a demand for nonsurgical treatment. AYP-101, which contains soybean phosphatidylcholine (SPC), is under investigation for SMF reduction. This study aimed to compare 2 concentrations of AYP-101 to placebo injections to determine the optimal concentration and evaluate safety and efficacy in reducing moderate to...

Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II

Abstract summary (English) BACKGROUND: Submental fat (SMF) is a common aesthetic concern traditionally treated with liposuction. Nonsurgical alternatives, like injectable deoxycholic acid, are gaining popularity. However, no related products have been clinically approved in China.

Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase III

Abstract summary (English) INTRODUCTION: The study investigates the efficacy of combining low-dose triamcinolone acetonide (TAC) and lidocaine with deoxycholic acid (DCA) injections to reduce adverse effects (AEs) without compromising long-term results. METHODS: A double-blind, randomized trial was conducted with 15 subjects, divided into a control group (DCA with lidocaine) and an intervention group (DCA with low-dose TAC and lidocaine). The...

Journal Article, Randomized Controlled Trial

Abstract summary (English) BACKGROUND: Deoxycholate is approved for submental fat reduction due to its ability to lyse cells and reduce fat accumulation, but it is used off-label in aesthetic treatments for subcutaneous fat reduction for several other parts of the body. OBJECTIVE: Review the clinical evidence supporting using sodium deoxycholate and delivery systems for aesthetic purposes. MATERIALS AND METHODS: This systematic review...

Journal Article, Systematic Review, Research Support, Non-U.S. Gov't

Abstract summary (English) BACKGROUND: Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.

Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial

Abstract summary (English) Lipolytic substance injections to reduce localized fat have been extensively used because it is a low-invasive method. This review aimed to evaluate the efficacy and safety of deoxycholic acid in submental fat reduction compared to a placebo and investigate the potential industry sponsorship bias in the results of randomized clinical trials on this topic. Ten electronic databases were extensively searched for...

Meta-Analysis, Systematic Review, Journal Article

Abstract summary (English) BACKGROUND: Tapencarium (RZL-012) (5-(3.6-dibromo-9H-carbazol-9-yl)-N, N, N-trimethylpentan-1-aminium chloride) is a novel injectable synthetic molecule with cytolytic properties, capable of reducing subcutaneous fat volume. OBJECTIVES: The goal of this 3-armed, randomized, double-blind, placebo-controlled phase 2b study was to determine the safety and efficacy of low- and high-dose RZL-012 vs placebo on submental...

Randomized Controlled Trial, Journal Article

Abstract summary (English) The accumulation of submental fat (SMF) can negatively impact facial harmony appearance, and one alternative treatment for this condition is the application of deoxycholic acid (DOC). The objective of this systematic review was to answer the following question: "Is DOC able to reduce SMF and increase patient satisfaction when compared to the placebo groups?". Therefore, a detailed search strategy was carried out in...

Systematic Review, Journal Article

Abstract summary (English) Excessive accumulation of submental fat (SMF) causes a lower face cosmetic problem. A lipolytic injectable has recently been developed as a solution. The objective of this study is to investigate the effects and safety of DWJ211 (a newly developed lipolytic injectable) in the reduction of SMF and to identify the optimum dose.

Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial

Abstract summary (English) BACKGROUND: Beyond submental fat reduction, injectable deoxycholic acid (DCA) has gained popularity in recent years for various minimally invasive lipolysis applications. OBJECTIVE: To summarize and evaluate the evidence of off-label uses of injectable DCA. METHODS: MEDLINE, Embase, CINAHL, Web of Science, and CENTRAL were searched.

Journal Article, Systematic Review